HMGA1 Regulates IRS2 to Promote Inflammatory Responses and Oxidative Stress Injury in MPP+-Induced cells
- PMID: 39244689
- DOI: 10.1007/s12013-024-01510-7
HMGA1 Regulates IRS2 to Promote Inflammatory Responses and Oxidative Stress Injury in MPP+-Induced cells
Abstract
Parkinson's disease (PD) is a prevalent neurodegenerative disorder for which novel treatment approaches are continuously sought. This study investigates the role of high-mobility group A1 (HMGA1) in modulating inflammatory responses and oxidative stress injury in PD. We utilized the murine dopaminergic neuronal cell line MN9D, treating cells with 1-methyl-4-phenylpyridinium ion (MPP+) to mimic PD conditions. The expression levels of HMGA1 and insulin receptor substrate 2 (IRS2) were measured using quantitative polymerase chain reaction and Western blot assay. Cell damage was assessed with cell counting kit-8 and lactate dehydrogenase assays. Inflammatory response and oxidative stress were evaluated by quantifying interleukin (IL)-1β, IL-6, tumor necrosis factor-α, reactive oxygen species, superoxide dismutase, and malondialdehyde (MDA) levels using enzyme-linked immunosorbent assay and commercial kits. The binding interaction between HMGA1 and IRS2 was analyzed using chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. Our findings revealed that MPP+ treatment increased the expression of HMGA1 and IRS2. Downregulation of HMGA1 enhanced cell viability, reduced inflammation, and mitigated oxidative stress in MPP+-induced cells. Further investigation demonstrated that HMGA1 bounded to the IRS2 promoter, enhancing IRS2 expression. Overexpression of IRS2 counteracted the protective effects of HMGA1 downregulation. In conclusion, HMGA1 exacerbates MPP+-induced cell damage by activating IRS2 transcription, which in turn heightens inflammation and oxidative stress. These findings suggest that targeting HMGA1 could be a potential therapeutic strategy for PD.
Keywords: HMGA1; IRS2; MPP+; Oxidative stress; Parkinson’s disease.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Compliance with Ethical Standards. Conflict of interest: The authors declare no competing interests.
References
-
- Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021). Challenges in the diagnosis of Parkinson’s disease. Lancet Neurology, 20(5), 385–397. https://doi.org/10.1016/S1474-4422(21)00030-2 . - DOI - PubMed
-
- Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson’s disease. Journal of Neural Transmission, 124(8), 901–905. https://doi.org/10.1007/s00702-017-1686-y . - DOI - PubMed
-
- Dias, V., Junn, E., & Mouradian, M. M. (2013). The role of oxidative stress in Parkinson’s disease. Journal of Parkinsons Disease, 3(4), 461–491. https://doi.org/10.3233/JPD-130230 . - DOI
-
- Yildizhan, K., & Naziroglu, M. (2020). Glutathione depletion and Parkinsonian neurotoxin MPP+-induced TRPM2 channel activation play central roles in oxidative cytotoxicity and inflammation in microglia. Molecular Neurobiology, 57(8), 3508–3525. https://doi.org/10.1007/s12035-020-01974-7 .
-
- Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: a review. JAMA, 323(6), 548–560. https://doi.org/10.1001/jama.2019.22360 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
